Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-12428425-B2 · Sep 30, 2025 · US
This page is not indexed by search engines while we improve data quality.
Bos Maxence patents
Bos Maxence is listed as an inventor on 8 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Bos Maxence |
| Total patents | 8 |
| First publication | Jan 5, 2023 |
| Latest publication | Sep 30, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-2024182477-A1 · Jun 6, 2024 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-11912711-B2 · Feb 27, 2024 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-11884675-B2 · Jan 30, 2024 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-2023295169-A1 · Sep 21, 2023 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-2023295170-A1 · Sep 21, 2023 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-11608344-B2 · Mar 21, 2023 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US-2023002390-A1 · Jan 5, 2023 · US
Recent patents
Latest publications not already listed above.
No data yet.
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Amgen Inc | 8 |
| Vigil Neuroscience Inc | 8 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61K31/4985 | 8 |
| A61K31/5377 | 8 |
| C07D475/00 | 8 |
| C07D471/04 | 8 |
| C07D413/14 | 8 |